Free Trial Information
BioCentury | Mar 15, 2010
Company News

Solasia, Kyowa Hakko Kirin deal

...Solasia (formerly JapanBridge K.K. ) granted Kyowa exclusive rights in Taiwan, Hong Kong, Singapore and Malaysia to...
Read More
BioCentury | Mar 16, 2009
Clinical News

Sancusco granistron patch: Phase I started

...Phase I trial to evaluate Sancuso granisetron patch (SP-01) in healthy Japanese volunteers. Solasia (formerly JapanBridge K.K....
Read More
BioCentury | Feb 16, 2009
Company News

Invida Pharmaceutical Holdings Pte. Ltd., ProStrakan sales and marketing update

...receptor antagonist is approved in the U.S. for CINV and is under review in Europe. JapanBridge K.K....
Read More
BioCentury | Jan 12, 2009
Finance

New products to watch

...migraine U.S. Progenics (NASDAQ:PGNX)/ Wyeth (NYSE:WYE) Subcutaneous Relistor methylnaltrexone Opioid-induced constipation (OIC) U.S./EU ProStrakan (LSE:PSK)/ JapanBridge...
Read More
BioCentury | Oct 6, 2008
Finance

3Q approvals

...to treat opioid-induced constipation (OIC) in patients receiving palliative care ProStrakan (LSE:PSK)/ Solasia Pharma (formerly JapanBridge...
Read More
BioCentury | Sep 22, 2008
Clinical News

Sancuso regulatory update

...FDA postponed the decision date several times due to resource constraints (see BioCentury, July 21). JapanBridge K.K....
Read More
BioCentury | Jul 21, 2008
Clinical News

Sancuso regulatory update

...product also is under review in the EU, where the launch is expected in 1H09. JapanBridge K.K....
Read More
BioCentury | Jul 14, 2008
Clinical News

Sancuso regulatory update

...product also is under review in the EU, where the launch is expected in 1H09. JapanBridge K.K....
Read More
BioCentury | Jun 2, 2008
Company News

JapanBridge board of directors update

JapanBridge K.K. , Tokyo, Japan Business: Cancer Appointed: Masahiro Michisuji, an advisor to Novartis AG 's Novartis Pharma K.K. unit WIR Staff cancer...
Read More
BioCentury | Jun 2, 2008
Company News

JapanBridge scientific advisory board update

JapanBridge K.K. , Tokyo, Japan Business: Cancer Appointed: George Daley, associate professor of biological chemistry and molecular pharmacology at Harvard Medical School; Kazuto Nishio, professor and chairman of the department of genome biology at Kinki University...
Read More
Items per page:
1 - 10 of 16
BioCentury | Mar 15, 2010
Company News

Solasia, Kyowa Hakko Kirin deal

...Solasia (formerly JapanBridge K.K. ) granted Kyowa exclusive rights in Taiwan, Hong Kong, Singapore and Malaysia to...
Read More
BioCentury | Mar 16, 2009
Clinical News

Sancusco granistron patch: Phase I started

...Phase I trial to evaluate Sancuso granisetron patch (SP-01) in healthy Japanese volunteers. Solasia (formerly JapanBridge K.K....
Read More
BioCentury | Feb 16, 2009
Company News

Invida Pharmaceutical Holdings Pte. Ltd., ProStrakan sales and marketing update

...receptor antagonist is approved in the U.S. for CINV and is under review in Europe. JapanBridge K.K....
Read More
BioCentury | Jan 12, 2009
Finance

New products to watch

...migraine U.S. Progenics (NASDAQ:PGNX)/ Wyeth (NYSE:WYE) Subcutaneous Relistor methylnaltrexone Opioid-induced constipation (OIC) U.S./EU ProStrakan (LSE:PSK)/ JapanBridge...
Read More
BioCentury | Oct 6, 2008
Finance

3Q approvals

...to treat opioid-induced constipation (OIC) in patients receiving palliative care ProStrakan (LSE:PSK)/ Solasia Pharma (formerly JapanBridge...
Read More
BioCentury | Sep 22, 2008
Clinical News

Sancuso regulatory update

...FDA postponed the decision date several times due to resource constraints (see BioCentury, July 21). JapanBridge K.K....
Read More
BioCentury | Jul 21, 2008
Clinical News

Sancuso regulatory update

...product also is under review in the EU, where the launch is expected in 1H09. JapanBridge K.K....
Read More
BioCentury | Jul 14, 2008
Clinical News

Sancuso regulatory update

...product also is under review in the EU, where the launch is expected in 1H09. JapanBridge K.K....
Read More
BioCentury | Jun 2, 2008
Company News

JapanBridge board of directors update

JapanBridge K.K. , Tokyo, Japan Business: Cancer Appointed: Masahiro Michisuji, an advisor to Novartis AG 's Novartis Pharma K.K. unit WIR Staff cancer...
Read More
BioCentury | Jun 2, 2008
Company News

JapanBridge scientific advisory board update

JapanBridge K.K. , Tokyo, Japan Business: Cancer Appointed: George Daley, associate professor of biological chemistry and molecular pharmacology at Harvard Medical School; Kazuto Nishio, professor and chairman of the department of genome biology at Kinki University...
Read More
Items per page:
1 - 10 of 16